Is There a Role for KRAS Inhibitors in the First-Line Treatment of NSCLC?

Opinion
Video

This video segment explores the potential role of KRAS-targeted therapies in the frontline treatment of KRAS-positive metastatic NSCLC, highlighting considerations for specific patient populations and disease characteristics.

Video content above is prompted by the following:

  • In your opinion, is there a place for these treatments in the frontline treatment of KRAS+ metastatic NSCLC?
Recent Videos
Two experts are featured in this series.
Two experts are featured in this series.
Two experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Two experts are featured in this series.
Two experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Related Content
Developers have outlined plans to initiate a randomized phase 2 trial evaluating silevertinib in patients with newly diagnosed glioblastoma.

Silevertinib Displays Robust Antitumor Activity in EGFR-Mutated NSCLC

Roman Fabbricatore
December 4th 2025
Article

Developers have outlined plans to initiate a randomized phase 2 trial evaluating silevertinib in patients with newly diagnosed glioblastoma.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

No dose-limiting toxicities were observed among 12 patients with advanced EGFR-mutated NSCLC treated with quaratusugene ozeplasmid and osimertinib.

Non-Viral Gene Therapy Displays Feasibility in EGFR-Mutated NSCLC

Roman Fabbricatore
November 24th 2025
Article

No dose-limiting toxicities were observed among 12 patients with advanced EGFR-mutated NSCLC treated with quaratusugene ozeplasmid and osimertinib.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 4th 2025
Podcast

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Results from the SOHO-01 trial led to the approval of sevabertinib for patients with non-squamous NSCLC.

FDA Approves Sevabertinib in Non-Squamous NSCLC

Tim Cortese
November 19th 2025
Article

Results from the SOHO-01 trial led to the approval of sevabertinib for patients with non-squamous NSCLC.

The regulatory decision regarding the subcutaneous pembrolizumab formulation is based on results from the phase 3 3475A-D77 trial.

EU Approves Subcutaneous Pembrolizumab in All Approved Indications

Roman Fabbricatore
November 19th 2025
Article

The regulatory decision regarding the subcutaneous pembrolizumab formulation is based on results from the phase 3 3475A-D77 trial.